Last reviewed · How we verify

NCT04473651

Safety and Tolerability of Lu AG06479 in Healthy Young Men

Terminated Phase 1 Last updated 14 December 2021
What this trial tests

Phase 1 trial testing Lu AG06479 in Healthy in 46 participants. Terminated before completion.

Timeline
9 July 2020
Primary endpoint
10 November 2021
10 November 2021

Quick facts

Lead sponsorH. Lundbeck A/S
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposetreatment
Enrollment46
Start date9 July 2020
Primary completion10 November 2021
Estimated completion10 November 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

H. Lundbeck A/S — full company profile →

Who can join

Adults 18 to 45, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other H. Lundbeck A/S trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04473651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing